Biocon Ltd, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals

RELATED ARTICLES Pharma companies deny wrongdoing in introducing new drugs

business, its Chairman and Managing Director said on Wednesday.

The Bangalore-based drugmaker earlier said consolidated net profit fell 15.8 percent in December quarter, while revenue rose 3 percent.

The sales growth in the fiscal third quarter ended December 31 was flat on lower licensing income, Kiran Mazumdar-Shaw, told a television channel.

The company said, licensing fees and income dropped to 292 million rupees in October-December from Rs 768 million a year earlier.